Despite the fundamental pathophysiological importance of b-catenin in tumor progression, the mechanism underlying its final transcriptional output has been partially elucidated. Here, we report that b-arrestin-1 (b-arr1) is an epigenetic regulator of endothelin (ET)-1-induced b-catenin signaling in epithelial ovarian cancer (EOC). In response to ET A receptor (ET A R) activation by ET-1, b-arr1 increases its nuclear translocation and direct binding to b-catenin. This in turn enhanced b-catenin nuclear accumulation and transcriptional activity, which was prevented by expressing a mutant b-arr1 incapable of nuclear distribution. b-arr1-b-catenin interaction controls b-catenin target gene expressions, such as ET-1, Axin 2, Matrix metalloproteinase 2, and Cyclin D1, by promoting histone deacetylase 1 (HDAC1) dissociation and the recruitment of p300 acetyltransferase on these promoter genes, resulting in enhanced H3 and H4 histone acetylation, and gene transcription, required for cell migration, invasion and epithelial-to-mesenchymal transition. These effects are abrogated by b-arr1 silencing or by mutant b-arr1, as well as by b-catenin or p300 silencing, confirming that nuclear b-arr1 forms a functional complex capable of regulating epigenetic changes in b-catenindriven invasive behavior. In a murine orthotopic model of metastatic human EOC, silencing of b-arr1 or mutant b-arr1 expression, as well as ET A R blockade, inhibits metastasis. In human EOC tissues, b-arr1-b-catenin nuclear complexes are selectively enriched at b-catenin target gene promoters, correlating with tumor grade, confirming a direct in vivo b-arr1-b-catenin association at specific set of genes involved in EOC progression. Collectively, our study provides insights into how a b-arr1-mediated epigenetic mechanism controls b-catenin activity, unraveling new components required for its nuclear function in promoting metastasis.
INTRODUCTION

Epithelial ovarian cancer (EOC) often features endothelin (ET)-1 and ET A receptor (ET A R) axis, which signals through the cytosolic scaffold proteins b-arrestins (b-arrs).
1,2 b-arrs, consisting of b-arr1 and b-arr2, are involved in G-protein-coupled receptor signaling, and guide the receptor signals also in malignant cells. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] A global proteomics analysis of b-arr1-interacting proteins demonstrated that b-arr1 interactions take place not only in the cytoplasm, but also in the nucleus, 13 suggesting that b-arr1 has a role in transcriptional regulation in different human cells. [14] [15] [16] Previous studies indicate that under d-or k-opioid receptor stimulations, nuclear b-arr1 specifically accumulates at p27 and c-fos promoters through scaffolding cyclic adenosine monophosphate responseelement (CRE) binding protein and histone acetyltransferase p300, thus enhancing local histone acetylation and gene transcription. 17 A similar mechanism was also observed during T-cell activation, in which nuclear b-arr1 increases Bcl-2 expression and contributes to CD4 þ T-cell survival. 18 Nuclear b-arr1 is also essential for the mitogenic and antiapoptotic activity of nicotine in human nonsmall cell lung cancer cells, through regulating the binding to E2F family of transcription factors. 19 Moreover, b-arr1 regulates nuclear signaling during hypoxia to promote survival of breast cancer cells by facilitating hypoxia-inducible factor-1-dependent vascular endothelial growth factor expression. 20 Recent results show that b-arr1, via the interaction with importin b1, is imported in the nucleus where it is able to recruit protein modifiers to p65/RelA, consequently increasing nuclear factor-kB transcriptional responsiveness. 21 However, the underlying mechanisms of b-arr1-mediated transcription regulation in pathophysiological conditions, such as cancer, still remain to be elucidated. Given that b-arr1 does not contain a discernible DNA-binding domain, 22 it is important to identify the nuclear interactions of b-arr1 and their functional implications in cancer progression.
b-arr was also reported to regulate Wnt/b-catenin signaling, which is aberrantly activated in human cancer and is required for tumor progression and stem cell regulation. [23] [24] [25] [26] [27] In this context, we previously demonstrated that downstream to ET A R, barr1 serves as a cytosolic scaffold for the stabilization of b-catenin. 5, 28 One feature of b-catenin signaling activation is its presence in the nucleus, where b-catenin initiates transcription as a member of multimeric complexes acting as the central transcriptional activator. Although several studies extensively depict many molecular mechanisms controlling b-catenin-mediated transcription, they do not completely explain how b-catenin gets into the nucleus to control transcription during metastatization. In this regard, we hypothesized that b-arr1, if indeed capable of nuclear function, would be endowed with a novel epigenetic mechanism by recruiting b-catenin to specific target gene promoters to activate transcription. Therefore, in an attempt to identify b-arr1-interacting transactivators, which bind to those promoters involved in tumor progression, we examined the nuclear interaction that connects b-arr1 to b-catenin signaling in EOC. In this study, we report that the nuclear transcriptional function of b-arr1 in response to ET A R activation represents a novel epigenetic mechanism involved in controlling b-catenin activity to promote epithelial-to-mesenchymal transition (EMT) and tumor metastasis, offering the possibility to develop new strategies for inhibiting ET A R/b-arr1/b-catenin-mediated tumor progression.
RESULTS
ET-1 induces nuclear translocation of b-arr1 in ovarian cancer cells As previously reported, 5 b-arr1 was able to shuttle from the cytoplasm to the cell membrane (Supplementary Figure S1A) to interact with ET A R within a few minutes of ET-1 treatment. In order to investigate whether ET-1 stimulation induces also the translocation of b-arr1 to the nucleus, we analyzed the subcellular localization of b-arr1 in the cytosolic and nuclear extracts from HEY, A2780 and OVCA 433 cells, endogenously expressing b-arr1. Immunoblotting analysis clearly showed that b-arr1, which in quiescent cells is localized predominantly in the cytosolic extracts, translocated to the nuclear compartment after ET-1 stimulation in a time-and dose-dependent manner (Figure 1a and Supplementary Figure S1B ). Nuclear accumulation of both endogenous b-arr1 ( Figure 1a ) and exogenous b-arr1-FLAG (Figure 1b ) increased by twofold after 15 min of ET-1 challenge, demonstrating that ET-1 promotes nuclear accumulation of b-arr1 in EOC cells and that this translocation is not an artifact of FLAGfusion or overexpression of b-arr1. Confocal laser scanning microscopy analysis in HEY and OVCA 433 cells stably expressing b-arr1-FLAG confirmed these results and revealed that ET-1 stimulation induced a strong nuclear translocation of b-arr1 after 15 min (Figure 1c and Supplementary Figure S1C) , and that was abrogated by treatment with zibotentan, a specific ET A R antagonist, indicating that b-arr1 nuclear translocation was mediated by ET A R (Figure 1c and Supplementary Figure S1C) .
As EOC cells express both b-arr1 and b-arr2, 5 we further analyzed the nucleocytoplasmic shuttling of both b-arr1 and b-arr2 on ET-1 treatment in HEY cells transiently expressing b-arr1-green fluorescent protein (GFP) or b-arr2-yellow fluorescent protein (YFP). Both b-arr1 and b-arr2 are able to move between the cytoplasm and nucleus but b-arr2 possesses a strong nuclear export signal in its C terminus, which hinders its retention in the nucleus. 17, 29, 30 Before ET-1 stimulation, b-arr1-GFP fluorescence was distributed preferentially in the cytoplasm, although a faint Figure 1 . b-arr1 localizes in the nucleus on activation of ET A R by ET-1. HEY, A2780 and OVCA 433 cells expressing endogenous b-arr1 (a) or HEY cells expressing b-arr1-FLAG (b) were treated with ET-1 for the indicated times, and cytoplasmic and nuclear extracts were subjected to immunoblotting (IB) for b-arr1 or FLAG. The average of nuclear b-arr1 in the graphics showed in (a, b) corresponds to the quantification of protein bands in images from three independent experiments, normalized to proliferating cell nuclear antigen (PCNA) content ±s.e.m. b-arr1 localization by confocal laser scanning microscopy (CLSM) examination (three-dimensional reconstruction images) in HEY cells expressing b-arr1-FLAG (c) stimulated for 15, 30 or 60 min with 100 nM ET-1 and/or 1 mM zibotentan for 15 min, or expressing b-arr1-Q394L-FLAG (d), stimulated for 15 min with ET-1, and stained with an anti-FLAG Ab. Nuclei are reported in blue (4 0 ,6-diamidino-2-phenylindole (DAPI)). Scale bars ¼ 20 mm.
fluorescence could be detected in the nucleus, and b-arr2-YFP was confined solely to the cytoplasm. Whereas, ET-1 treatment induced a strong nuclear accumulation of b-arr1-GFP but not barr2-YFP (Supplementary Figure S1D) . Then, we transfected HEY and OVCA 433 cells with b-arr1-Q394L mutant, in which the nuclear export signal of b-arr2 was introduced into b-arr1, by a single point (Q394L) mutation. 17, 29, 30 and we observed that the nuclear distribution of b-arr1 was inhibited on ET-1 challenge (Figure 1d, Supplementary Figures S1C and S1F) . Moreover, the treatment with 10 nM Leptomycin B, an inhibitor of nuclear export signal-mediated active nuclear export, induced a strong nuclear accumulation of b-arr2-YFP in both basal and ET-1-treated conditions but not appreciable effects regarding the subcellular distribution of endogenous or exogenous b-arr1 (GFP or FLAG) were observed (Supplementary Figures S1D, S1E and S1G), indicating that ET-1 controls the nuclear trafficking of b-arr1 most likely to modulate nuclear signaling of ET A R in EOC cells. Figure S2C ). To further explore the nuclear functions of b-arr1, we used four b-arr1 deletion mutants tagged with an AU5 epitope at their carboxyl termini, 21, 31 and expressed them in HEY cells. As shown in Figure 2d , of the four b-arr1 mutants, three were found to be correlated with b-catenin. The b-arr1-1-180S mutant, deleted of the region required for its nuclear localization, 21 was not co-IP with the b-catenin, suggesting that this truncated b-arr1 construct was unable to interact with it. Given that both b-arr1-1-180S and b-arr1-1-90N were found to associate with b-catenin, these results suggested that the deletion of a region consisting of amino acids 1-180 of b-arr1, containing the nuclear localization signal, leads to a loss of b-arr1-b-catenin interaction. Altogether, these findings indicate that b-arr1 functions as a chaperone of ET A R in regulating b-catenin nuclear localization.
Furthermore, the endogenous TCF4 protein, a well-known binding partner of b-catenin, was detected in the b-arr1 and bcatenin nuclear IPs, and its levels increased following ET-1 treatment (Figure 2e and Supplementary Figure S2E ). In these nuclear IPs, the silencing of TCF4 reduced the ET-1-induced nuclear interaction between b-arr1 and b-catenin, demonstrating that the b-catenin-TCF4 complex interacts with b-arr1 in the nucleus of EOC cells (Supplementary Figure S2F) .
To analyze whether this nuclear association might be directly associated with the transcriptional activity of b-catenin/TCF4 by the recruitment on its target genes, we assessed the effects of gain-loss function of b-arr1 on b-catenin transactivating function by using the TopFlash or FopFlash luciferase reporter. The transcriptional activity of b-catenin induced by ET-1 was inhibited by silencing b-arr1 and rescued by the re-expression of b-arr1-FLAG, but not by b-arr1-Q394L, or b-arr1-1-180S mutant ( Figure 2f and Supplementary Figures S3A and B) , confirming that ET A Rdriven nuclear b-arr1 binds to b-catenin. This interaction is necessary for inducing b-catenin/TCF4 transcriptional activity. In the absence of b-catenin binding, the promoters of b-catenin target genes are occupied by TCF/LEF family proteins and corepressors of Groucho/TLE1 and histone deacetylase 1 (HDAC1), 36 rendering the chromatin more compact and transcriptionally inactive. To determine whether b-arr1 has a role in regulating the function of the b-catenin/TCF4 complex at the target promoters, we first probed the association of TCF4 and HDAC1 with b-catenin target gene promoters. ChIP assays showed that, in untreated cells, HDAC1 was associated with the ET-1 and MMP-2 promoters, whereas ET-1 treatment led to a substantial decrease in HDAC1 and ET-1 and MMP-2 promoter interactions ( Figure 4a ). Interestingly, b-arr1 knockdown dramatically enhanced HDAC1 association with both promoters (Figure 4a ). This supports the hypothesis that b-arr1 promoted dissociation of TCF4-bound HDAC1 from b-catenin target gene promoters and accumulation of nuclear b-catenin/TCF4 complex competent to activate the expression of downstream target genes. p300 interacts with b-arr1 and b-catenin to mediate histone H3 and H4 acetylation on b-catenin-dependent transcription Given the role of histone acetyltransferase p300 in b-arr1-mediated gene expression, 17 we assessed whether b-arr1 could form a multimeric complex with b-catenin and with p300 in the nucleus by combinatorial IP. In HEY cells, ET-1 treatment promoted the association of b-arr1 with p300 and b-catenin in the nucleus, as detected in b-arr1, p300 and b-catenin IPs (Figure 4b induced a loss in the ability to bind between the other two components of the transcriptional complex (Figure 4b ), suggesting that b-arr1 may provide a nuclear anchor for p300 and b-catenin as a prerequisite for b-catenin-mediated transcription. ChIP assays showed that ET-1 treatment induced a timedependent recruitment of p300, as well as b-catenin, on ET-1, MMP-2, and Cyclin D1 promoters (Figure 4c ). b-arr1 silencing, or b-arr1-Q394L expression, significantly inhibited the recruitment of both p300 and b-catenin on these promoters (Figure 4d) . Moreover, on ET-1 stimulation, b-arr1, b-catenin and p300 cooccupied the ETP (Figure 4e ), confirming that nuclear b-arr1 is involved in recruiting p300 and b-catenin to the target genomic regions of b-catenin, as demonstrated by ChIP-re-ChIP assays. Altogether, these results reveal that b-arr1 might promote the dissociation of HDAC1 from b-catenin/TCF4 nuclear complex while increasing p300 binding to the b-catenin target gene promoters.
The potential role of b-arr1 in p300-mediated gene-specific acetylation was then investigated. ET-1 stimulation enhanced time-dependent recruitment of H3 and H4 acetylated and of b-catenin, b-arr1 and p300 on ET-1 and MMP-2 promoters (Figure 5a ). Moreover, in ET-1-treated cells silenced for b-arr1, or for b-catenin, or expressing b-arr1-Q394L, or in cells transfected with p300DHAT, carrying a deletion of p300 acetyltransferase domain, no acetylation of histone H3 and H4 was observed (Figure 5b ). Among the conserved lysine residues susceptible to acetylation by p300 in histone H3, 37 ET-1 treatment increased the levels of both lysine 18 and 27 of histone H3 (H3K18Ac and H3K27Ac) on ET-1, MMP-2 and Cyclin D1 promoters. Moreover, these acetylations were significantly reduced in cells silenced for 32, 33 To determine the presence of the multimeric complex on each TBE site on the ETP together with acetylated H3 and H4, we performed ChIP assays using pairs for three specific promoter fragments, from À 1798 to À 22-bp surrounding the transcriptional initiation site of the ET-1 gene, containing TBE 1, 2, 3-4, or for a promoter fragment not containing TBE. ET-1 enhanced acetylation of H3 and H4 and recruitment of b-arr1, b-catenin and p300 on ETP in all four TBE regions, but not in the not containing TBE region (Supplementary Figure S5C) , indicating that that b-arr1 is critically involved in promoting histone acetylation of H3 and H4 at the ET-1 locus containing the binding elements for b-catenin. At a functional level, we tested the role of nuclear b-arr1 in the activity of a reporter gene with a human ETP sequence spanning À 1300 to þ 230-bp surrounding the transcriptional initiation site and containing only a functional TBE located at À 73 to À 67 bp and a mutant reporter construct (muETP) generated by deleting the functional TBE from the ETP. 32 Deletion of the functional TBE completely abolished the ETP activity (Figure 5e ). More importantly, the overexpression of exogenous b-arr1, but not b-arr1- Figures S5D and S5E ). These effects were rescued by the re-expression of exogenous b-arr1, but not by the mutant b-arr1-Q394L, indicating that b-arr1 specifically binds to b-catenin and transactivates the specific gene promoters (Figure 5f and Supplementary Figure S5F) . Altogether, these results showed that recruitment of p300 and b-arr1 to b-catenin-responsive promoters was a specific event induced by ET-1/ET A R in EOC cells. The formation of this nuclear complex regulates histone acetylation in specific chromosomal regions, which is most likely the mechanism upregulating ET-1, MMP-2 and Cyclin D1 expression.
Nuclear b-arr1 is required for ET A R-mediated invasive behavior To examine whether nuclear b-arr1 was essential for ET A Rmediated b-catenin regulated genes involved in cell motility, we performed migration and invasion assays in HEY cells. Cell (Figures 6a and b) . Most importantly, the reexpression of b-arr1, but not mutant b-arr1-Q394L, was able to rescue the ability of these cells to migrate and invade (Figures 6a  and b) , confirming that nuclear b-arr1 is a check-point of invasive signals in EOC cells. Given the role of ET-1/ET A R axis in inducing EMT in EOC cells previously demonstrated, we analyzed whether nuclear b-arr1 was also involved in ET A R-driven molecular changes consistent with EMT, 38,39 a key mechanism that induces invasion and metastasis. 40 To this end, we examined the expression of the epithelial marker E-cadherin and its transcriptional regulators, Snail, Slug and Twist, and other mesenchymal markers, such N-cadherin. Downregulation of mRNA expression levels for Snail, Slug, Twist and N-cadherin and in parallel upregulation of E-cadherin was observed in HEY cells silenced for b-arr1 (Figure 6c) . Moreover, the re-expression of b-arr1, but not b-arr1-Q394L, reverted the expression of EMT markers, confirming the role of nuclear b-arr1 in inducing invasive behavior and EMT in these cells.
Loss of b-arr1 inhibits metastatic potential of ovarian cancer xenografts To demonstrate that nuclear b-arr1 is required for metastatization in vivo, we implanted parental HEY cells or HEY cells stably depleted of b-arr1 by short hairpin RNAs (shRNA) and/or reexpressing b-arr1 or mutant b-arr1-Q394L into the peritoneal cavity (orthotopic site) of female nude mice and followed their metastatization pattern on the peritoneal surface, omentum, small bowel, mesentery, and in both ovaries (Figure 7a and Supplementary Figure S6A) . Two groups of mice were injected with parental HEY cells, and after 1 week were treated with vehicle Figure S6A) , in a manner that mimicked the effects of zibotentan treatment. Moreover, consistent with in vitro results, the re-expression of b-arr1 was sufficient to induce metastasis, whereas the expression of b-arr1-Q394L reduced the metastatic spread (Figure 7a) .
To assess whether b-arr1 and b-catenin were selectively enriched at the ET-1, MMP-2 and Cyclin D1 promoters in vivo, we performed ChIP assays in metastatic nodules from different groups of mice. We detected binding between these promoters and b-arr1 and b-catenin in metastases from scramble Mocktransfected cells but not in metastases from sh-b-arr1-Mock (Figure 7b ) demonstrating in vivo that the recruitment of nuclear b-arr1 and b-catenin to b-catenin-responsive promoters was a critical event induced by ET A R in promoting metastastic diffusion during EOC progression.
b-arr1-b-catenin nuclear complexes in human ovarian carcinomas To more directly probe the in vivo association between b-arr1 and b-catenin to its responsive promoters in human ovarian cancer tissues, ChIP assays were performed on 20 advanced-stage EOC tumors and on two non-tumoral ovarian tissues. This analysis showed increased levels of b-arr1 and b-catenin associated with ET-1, Cyclin D1 and MMP-2 promoters in 70%, 80% and 80%, respectively, of tumor tissues analyzed compared with normal ovarian tissues (Figure 7c , Supplementary Table S1 and Supplementary Figure 6B) . Notably, increased levels of b-arr1 and b-catenin were associated with ET-1 (77%), Cyclin D1 (88%) and MMP-2 (88%) promoters in grade 3-4 tumors, whereas no grade 2 tumors co-expressed b-arr1 and b-catenin on these promoters. Together, these data provide further support for a direct and functional association between b-arr1 and b-catenin in human EOC samples at specific set of genes, correlating with tumor grade, and suggest that regulation of ET A R-driven gene expression by b-arr1 and b-catenin contributes to human EOC progression.
DISCUSSION
The b-catenin signaling pathway is aberrantly activated in human cancers and its activation results in dramatic changes in chromatin remodeling. 23 A key feature of this signaling activation is b-catenin nuclear localization, for which the underlying molecular mechanisms remain elusive. Here, we show a unique function of b-arr1 required for nuclear b-catenin activity in promoting tumor metastasis. We demonstrated that in EOC cells, ET A R activation by ET-1 induces nuclear translocation of b-arr1. In the nucleus, b-arr1 interacts with b-catenin and p300 to form a functional complex with TCF4 on target-gene promoters, such as Axin 2, ET-1, Cyclin D1 and MMP-2, which have a key role during cell invasion. This functional platform is necessary for epigenetic modification, such as histone acetylation, and gene expression. Thus, in human EOC samples a tight association between nuclear b-arr1 and b-catenin occurs on ET-1, Cyclin D1 and MMP-2 promoters. Therefore, the b-arr1-b-catenin interaction represents an important mechanism for controlling EOC progression.
Recent results have highlighted a new role for b-arr1 by which G-protein-coupled receptor may regulate gene transcription, suggesting that this mechanism might mediate new biological functions of b-arr1 in pathophysiological conditions, such as cancer. [17] [18] [19] [20] Although proteomic analysis has revealed that b-arr1 may directly interact with many proteins, 13 no data have been previously reported regarding the interaction of b-arr1 with b-catenin. Apart from the role of b-arr1 into regulating b-catenin signaling in the cytosolic compartment, 5,25-27 our findings unveil a novel role of b-arr1 as a nuclear platform in b-catenin transcriptional activity, depending on its subcellular nuclear distribution thus accounting for the epigenetic modification and gene transcription of selected target genes. In particular, our findings identify b-arr1 as a new interacting partner of b-catenin in the nucleus, where it displaces HDAC1 and recruits histone acetylase p300 to specific gene promoters increasing local acetylation of H3 and H4 histones and transcription of genes critical in promoting invasive behavior. In this context, b-arr1 appears to control two critical and related aspects of b-catenin nuclear function: nuclear accumulation and assembly of a transcription activation complex. Hence, our study provides 
initial scaffold on which transcriptional regulatory complexes could be built to regulate different biological outcomes. Distinct b-arr1 complexes in fact can recruit or interact with factors that modulate the transcription of specific target genes orchestrating a network that regulates cell migration, EMT and metastasis formation. Despite the wealth of information documenting several aspects of ET-1 signaling in cancer, deciphering the complex signaling networks that are governed by ET-1 and that influence ET-1 autocrine circuit, is still incomplete. As ET-1 elicits pleiotropic activities, it would be intriguing to speculate whether these activities are mediated by chromatin remodeling in the regulation of transcription. Here, we demonstrated that ET-1/ET A R axis modulates the self-amplifying positive feedback loop of b-catenin-ET-1 through the nuclear function of b-arr1. Thus, ET-1 signaling through b-arr1 promotes the formation of a b-arr1/ b-catenin/p300 transcription complex on ETP region. Hence, one can envisage a reciprocal relationship in which ET-1 stabilizes b-catenin 38, 39 resulting in the autoregulatory b-catenin-mediated transcription of ET-1 itself.
Given the importance of b-catenin signaling in human cancers and stem cell regulation, 41, 42 our findings establish that ET A Rmediated nuclear import of b-arr1 might allow fine-tuning of responses during tumor progression through its interaction with b-catenin.
Of note, the in vivo results showing the active role of ET A Rdriven nuclear b-arr1 in metastatic dissemination, as well as the presence of b-arr1-b-catenin nuclear complexes in the metastatic nodules indicate that ET A R, in an b-arr1-b-catenin-dependent way, may engage a distinct set of genes, enabling EOC cells to invade and metastasize. Moreover, the present results also suggest that co-occupancy of b-arr1 and b-catenin on selected gene promoters in human EOC tissues is associated with advanced-stage tumors. The present findings, which are consistent with our previous observations reporting that co-expression of ET A R and b-arr1 in human EOC tissues may be indicative of the malignant phenotype, 5 and that ET A R overexpression was associated with the switch of cadherin expression, 38 highlight the pathobiological relevance of ET A R/b-arr1/b-catenin in the regulation of EMT and aggressive behavior. In conclusion, we propose a model in which ET-1 initiates direct interaction between b-arr1 and b-catenin to regulate epigenetic modifications driving EMT and tumor progression through forming a multiprotein complex. Therefore, b-arr1 promotes the compartmentalization of ET A R signaling, which mediates qualitative signal-dependent histone modification and gene transcription. Thus, ET A R blockade, which by preventing nuclear b-arr1-b-catenin association inhibits transcription of genes that trigger EMT and metastatic process, may represent a targeted therapeutic approach that warrants exploration in EOC treatment. 43, 44 
MATERIALS AND METHODS
Cell lines and reagents
Established human ovarian serous adenocarcinoma cell lines, HEY and OVCA 433, obtained by Professor Giovanni Scambia (Catholic University School of Medicine, Rome, Italy), and A2780, purchased from European Collection of Cell Cultures (Salisbury, UK), cultured as previously described, 42, 45 were passaged in our laboratory for o3 months after resuscitation. All cells were tested routinely for cell proliferation ( 
Fluorescence microscopy analysis
Cells transfected with b-arr1-FLAG were fixed in 2% formaldheyde, permeabilized with 0.25% Triton-X 100 and then immunostained with the primary Ab to FLAG (Sigma-Aldrich) and to b-catenin (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and counterstained with 4 0 ,6-diamidino-2-phenylindole. Confocal laser scanning microscopy observations were performed with a Leica TCS SP2 AOBS apparatus, using 63 Â / 1.4 NA objective and excitation spectral laser lines at 405, 488 and 594 nm and using the Leica Confocal Software (Leica Lasertechnik version 2.6 rel. 1537, Heidelberg, Germany) and Adobe Photoshop software programs (Adobe system Incorporated, Rome, Italy). Signals from different fluorescent probes were taken in sequential scan mode (three-dimensional reconstruction images) and colocalization was visualized in merge images. Further details are given in Supplementary Methods.
Immunoblotting and IP
Cells were lysed in lysis buffer (250 mM NaCl, 50 mM HEPES (pH 7.4), 1 mM EDTA, 1% Nonidet P-40, protease inhibitors). NE-PER nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific, Illkirch-Cedex, France) were used to separate cytoplasmic and nuclear fractions. For their stable expression, transfected cells were selected by using 500 mg/ml G418 sulfate (Calbiochem-Novabiochem Corporation, San Diego, CA, USA). G418-resistant cells were pooled 3 weeks after transfection and thereafter cells were maintained in media containing 500 mg/ml of G418.
For transient expression of full-length or four different b-arr1 deletion mutants, we used constructs tagged with an AU5 epitope at their carboxyl termini kindly provided by Professor Richard D Ye (Department of Pharmacology, College of Medicine, University of Illinois, Chicago, IL, USA) and transfected using LipofectAMINE 2000 reagent (Life Technologies Italia).
To evaluate the role of p300, we used a full-length p300 construct, kindly provided by Professor Vittorio Sartorelli (Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA) and a p300DHAT construct (carrying a deletion of p300 acetyltransferase domain 1603-1658), kindly provided by Dr A Felsani (CNR, Institute of Neurobiology and Molecular Medicine, Rome, Italy).
RNA silencing
The small inhibitor duplex RNAs (small interfering RNA) were from Dharmacon (Fisher Scientific, Illkirch Cedex , France) and were human ON-TARGET plus SMART pool si-b-catenin #L-003482-00-0050, si-p300: #L-003486-00-0050, si-ET A R: #L-005485-00-0050. The siCONTROL Nontargeting Pool (#D-001810-10-20) was used as negative control. Cells were transfected with 100 nmol/l small interfering RNAs using LipofectAMINE reagent (Life Technologies Italia). After 48 h, total proteins were isolated and analyzed by immunoblotting analysis.
The lentiviral-based shRNAs plasmids (pLKO.1 plasmids) used to knockdown b-arr1 were purchased from Sigma-Aldrich. Five plasmidclones were tested for their knockdown efficiency (TRCN0000230149; b-arrestin-1 is an epigenetic regulator of b-catenin L Rosanò et al TRCN0000230147; TRCN0000005160; TRCN0000005161; TRCN0000230150). Non-Target shRNA Control Vector (SHC002) was used as negative control. Transient transfection was performed by adding shRNA plasmid along with LipofectAMINE 2000 (Life Technologies Italia) in six-well plates for 48 h (Supplementary Methods).
The silencer selected pre-designed and validated siTCF4 (#4392421) and silencer selected negative control #1 (Life Technologies Italia) were used to silence TCF4 and as negative control, respectively.
Reporter assay
Reporter activity was measured using the Luciferase assay system (Promega Corporation, Fitchburg, WI, USA) in cells co-transfected with pTOP/Flash or pFOP/Flash (Upstate Biotech, Billerica, MA, USA) or ETP reporter sequence and 100 ng pCMV-b-galactosidase (Promega Corporation) vectors using LipofectAMINE 2000 reagent (Life Technologies Italia). Luciferase assay were carried out according to standard procedures (Supplementary Methods).
Chromatin IP Chromatin was extracted from cells and ChIP was done as described in Supplementary Methods.
Enzyme-linked immunosorbent assay
The release of ET-1 in the conditioned media of serum-starved cells was measured in triplicate on microtiter plates by using an ET-1 ELISA kit (Phoenix Europe GmbH, Karlsruhe, Germany) according to the manufacturer's instructions.
Quantitative real-time PCR Total RNA was isolated using the Trizol (Life Technologies Italia) according to the manufacturer's protocol. First-strand complementary DNA was synthesized in a 20 ml reaction volume using SuperScript VILO cDNA synthesis kit (Life Technologies Italia). PCR reaction was performed using DNA Master Plus SYBR Green mix (Roche Diagnostics, Monza, Italy) according to the manufacturer's instructions. The number of each geneamplified product was normalized to the number of cyclophilin-A-amplified product. Each quantitative PCR analysis was done twice separately. The list of the primers used is shown in Supplementary Methods.
Chemotaxis and chemoinvasion assay
Cell chemotaxis and chemoinvasion assays were carried out using modified Boyden chambers consisting of transwell membrane filter inserts with 8 mm size polycarbonate membrane (chemotaxis) or precoated with polymerized collagen (chemoinvasion) placed in a 24-well plate (BD Biosciences, Franklin Lakes, NJ, USA), according to manufacturer's instructions (Supplementary Methods).
Metastasis assay
In all, 1.8 Â 10 6 HEY cells or clonally derived HEY cells stably expressing shRNA b-arr1 þ Mock or shRNA b-arr1 þ b-arr1-FLAG or shRNA b-arr1 þ barr1-Q394L-FLAG were injected intraperitoneally into female athymic nude mice (Charles River Laboratories, Milan, Italy), following the guidelines for animal experimentation of the Italian Ministry of Health. In all experiments, each group consisted of 10 mice. One week after injection of HEY cells, mice were treated for 4 weeks with vehicle (phosphate-buffered saline), or with zibotentan (10 mg/kg/day). Five weeks after injection of cancer cells, mice were killed; the number of metastases was counted and the removed tumors were measured, carefully dissected, and snap-frozen for ChIP analysis. Values represent the average ± s.e.m. of 10 mice from three independent experiments. *Po0.001 versus control or scramble-shRNAexpressing cells.
Patient data
Human tumor and normal ovarian specimens were kindly provided by Professor Gabriella Ferrandina from patients admitted to the Gynecologic Oncology Unit, Catholic University of Campobasso and Rome (Italy). Further details are given in Supplementary Methods.
Statistical analysis
Each experiment was repeated at least three times with comparable results, unless indicated otherwise. Results are expressed as mean±s.e.m. Differences between group were studied using analysis of variance followed by a Bonferroni post test. Statistical analysis was done with SPSS software (SPSS 11, SPSS Inc., Chicago, IL, USA).
